R Squared’s Trevi Therapeutics TRVI Stock Holding History

R Squared’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,320	Closed	-$9.56K	–	1425
2024 Q4	$9.56K	Buy	+2,320	New	+$7.43K	0.01%	1168

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

R Squared's TRVI Position: Q1 2025 in Review

R Squared sold out of Trevi Therapeutics (TRVI) in Q1 2025, closing a stake of 2,320 shares — an estimated $9.56K sold.

R Squared first reported a position in TRVI in Q4 2024 and held it in 1 quarter. The position peaked at $9.56K in Q4 2024. 137 funds tracked by Wall St. Rank hold TRVI as of Q1 2025.

R Squared reported no remaining Trevi Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,320 Trevi Therapeutics shares in Q1 2025, an estimated $9.56K.
R Squared first reported a position in Trevi Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Trevi Therapeutics position peaked at $9.56K in Q4 2024.
137 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.